Published in
MDPI, Viruses, 2(6), p. 391-403, 2014
DOI: 10.3390/v6020391
Links
- MDPI
- ORCID
- ORCID
- ORCID
- [www.ncbi.nlm.nih.gov] | PDF
- [europepmc.org] | PDF
- [www.researchgate.net] | PDF
- [www.ncbi.nlm.nih.gov] | PDF
- [www.ncbi.nlm.nih.gov] | PDF
Tools
Pseudo-Mannosylated DC-SIGN Ligands as Potential Adjuvants for HIV Vaccines
,
Patrizio Antonazzo,
Mara Biasin,
Irene Cetin ,
Daria Trabattoni,
Anna Bernardi,
Mario Clerici
Full text: Download
Abstract
The development of new and effective adjuvants may play a fundamental role in improving HIV vaccine efficacy. New classes of vaccine adjuvants activate innate immunity receptors, notably toll like receptors (TLRs). Adjuvants targeting the C-Type lectin receptor DC-SIGN may be alternative or complementary to adjuvants based on TRL activation. Herein we evaluate the ability of the glycomimetic DC-SIGN ligand Polyman 19 (PM 19) to modulate innate immune responses. Results showed that PM 19 alone, or in combination with TLR agonists, induces the expression of cytokines, β chemokines and co-stimulatory molecules that may, in turn, modulate adaptive immunity and exert anti-viral effects. These results indicate that the suitability of this compound as a vaccine adjuvant should be further evaluated.